dc.contributor.author | Paydas, Semra | |
dc.contributor.author | Turgut, Mehmet | |
dc.contributor.author | DEMİRKAN, FATİH | |
dc.contributor.author | Saydam, Giiray | |
dc.contributor.author | HAZNEDAROĞLU, İBRAHİM CELALETTİN | |
dc.contributor.author | Demir, Muzaffer | |
dc.contributor.author | AKSU, SALİH | |
dc.contributor.author | ŞAHİN, FAHRİ | |
dc.contributor.author | Uz, Burak | |
dc.contributor.author | Yavuz, Selim A. | |
dc.contributor.author | Atay, Hilmi | |
dc.contributor.author | KELKİTLİ, ENGİN | |
dc.contributor.author | PEHLİVAN, MUSTAFA | |
dc.contributor.author | Akay, Meltem O. | |
dc.contributor.author | Guray, Emel | |
dc.contributor.author | Kahraman, Selda | |
dc.date.accessioned | 2021-03-06T12:27:16Z | |
dc.date.available | 2021-03-06T12:27:16Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | AKSU S., ŞAHİN F., Uz B., Yavuz S. A. , Atay H., KELKİTLİ E., Turgut M., PEHLİVAN M., Akay M. O. , Guray E., et al., "The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia", UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, ss.8-14, 2012 | |
dc.identifier.issn | 1306-133X | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_f3e9adf9-fdf9-4286-8ae0-f9c870739e06 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/159933 | |
dc.identifier.uri | https://doi.org/10.4999/uhod.12004 | |
dc.description.abstract | We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia | |
dc.type | Makale | |
dc.relation.journal | UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | |
dc.contributor.department | Trakya Üniversitesi , , | |
dc.identifier.volume | 22 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 8 | |
dc.identifier.endpage | 14 | |
dc.contributor.firstauthorID | 203248 | |